CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

In a report released today, Carter Gould from Barclays maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the appointments of multiple senior leaders to its drug development team, ...

During the 37th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), held between 21-24 September 2024, new analyses of cariprazine studies were presented by Gedeon Richter Plc.

TRG, a privately owned, global managed services provider, announces today that it has merged capabilities with its TruWest Holdings sister company, Inversion6, and adds cybersecurity to its list of ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...